Evidence map›Paper›PMID 37777555›Full record

ArticleScientific reports2023

Simultaneous LC-MS/MS method for the quantitation of Azithromycin, Hydroxychloroquine and its metabolites in SARS-CoV-2(-/ +) populations using dried blood spots.

Yashpal S Chhonker, Wafaa N Aldhafiri, Dhruvkumar Soni, Neerja Trivedi, Claire Steinbronn, Christine Johnson, Helen C Stankiewicz Karita, Michael K Paasche-Orlow, Ruanne Barnabas, Samuel L Arnold and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Yashpal S Chhonker *Clinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, 68198-6025, USA. y.chhonker@unmc.edu.
Wafaa N Aldhafiri *Clinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, 68198-6025, USA.
Dhruvkumar SoniClinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, 68198-6025, USA.
Neerja TrivediClinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, 68198-6025, USA.
Claire SteinbronnDepartment of Pharmaceutics, University of Washington, Seattle, WA, 98195, USA.
Christine JohnsonDepartment of Medicine, University of Washington, Seattle, WA, 98195, USA.
Helen C Stankiewicz KaritaDepartment of Medicine, University of Washington, Seattle, WA, 98195, USA.
Michael K Paasche-OrlowDepartment of Medicine, Tufts Medical Center, Boston, MA, 02111, USA.
Ruanne BarnabasDivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA, 02114, USA.
Samuel L ArnoldDepartment of Pharmaceutics, University of Washington, Seattle, WA, 98195, USA.
Daryl J MurryClinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, 68198-6025, USA. dj.murry@unmc.edu.
University of Washington · USUniversity of Nebraska Medical Center · USNebraska Medical Center · USHarvard University · USTufts Medical Center · US

Funding

UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Joann B. Sweasy · 1985 to 2026
$55.0M
NCI NIH HHS P30 CA036727
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to a global pandemic of coronavirus disease 2019 (COVID-19). Early in the pandemic, efforts were made to test the SARS-CoV-2 antiviral efficacy of repurposed medications that were already approved and available for other indications, including hydroxychloroquine (HCQ) and azithromycin (AZI). To reduce the risk of SARS-CoV-2 exposure for clinical-trial study participants and to conform with lockdowns and social distancing guidelines, biospecimen collection for HCQ and AZI included at-home dried blood spot (DBS) collection rather than standard venipuncture by trained clinicians. In this study, we developed and validated the first sensitive and selective simultaneous LC-MS/MS method to accurately quantitate the concentration of HCQ, HCQ metabolites (Desethylchloroquine [DCQ], Bisdesethylchloroquine [BDCQ], Monodesethylhydroxychloroquine [DHCQ]) and AZI extracted from DBS. The validated method was successfully applied for the quantification of over 2000 DBS specimens to evaluate the pharmacokinetic profile of AZI, HQC, and its metabolites. This new method has a small sample volume requirement (~ 10 µL), results in high sensitivity (1 ng/mL), and would facilitate remotely conducted therapeutic drug monitoring.

Indexed as

COVID-19HydroxychloroquineAzithromycinChromatography, LiquidCommunicable Disease ControlCOVID-19 Drug TreatmentHumansSARS-CoV-2Tandem Mass SpectrometryAzithromycinHydroxychloroquine

Identifiers

PMID37777555
PMCPMC10542348
OpenAlexW4387222024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.